Drug intelligence / Profile preview

YG-01

Development stage: Preclinical
Lead developer: YGION Biomedical
Modality: Vaccines & Immunotherapeutics

Overview

YG-01 is a lead program developed by YGION Biomedical, an Austrian biotech company. It is an individualized neoantigen-based cancer vaccine designed to stimulate an immune response against cancer. The drug is currently being advanced into preclinical and clinical development, supported by a €15 million Series A financing round. It leverages YGION's proprietary YGNITE technology platform for creating personalized cancer vaccines.

Targets

Neoantigen-specific T-cell receptor

Beyond the preview

Go deeper on YG-01.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on YG-01.

Explore the full profile